Response by Wanner et al to Letters Regarding Article, “Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease”
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.